# EndoClot Plus

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/endoclot-plus

- Industry: Biotechnology
- Headquarters: Santa Clara, US
- Website: www.endoclot.com
- Latest round: Series B (Oct 26, 2018)
- Investors on record: 1

## About

EndoClot Plus, Inc. is a medical device company specializing in innovative solutions for gastrointestinal bleeding control, focusing on advanced hemostatic technologies for healthcare professionals.Founded in 2014 and headquartered in Santa Clara, US, EndoClot Plus, Inc. develops medical devices aimed at enhancing bleeding management in the gastrointestinal tract. The company has not undergone significant changes in its business strategy or structure since its inception. The current CEO, Patty Dodson, leads the company, building upon her previous experiences in the medical device industry. EndoClot Plus has raised a total of USD 1.00 mn in funding, with the most recent deal occurring on October 26, 2018, when they received SERIES B funding from Juming Venture.EndoClot Plus, Inc. specializes in innovative medical devices designed to address bleeding control in the gastrointestinal tract. Its flagship product, the EndoClot® Polysaccharide Hemostatic System (EndoClot® PHS), employs a proprietary powder that is sprayed directly onto wounds during endoscopic procedures. This technology aims to provide a rapid and effective method for managing gastrointestinal bleeding, a critical need for endoscopists and healthcare professionals in the field. In addition to the EndoClot® PHS, the company also offers the EndoClot® Adhesive and the EndoClot® Submucosal Injection System, which further enhance its portfolio of hemostatic solutions. EndoClot Plus serves a range of healthcare providers, including hospitals and specialized clinics, primarily within the United States and expanding into the Chinese market through its subsidiary, EndoClot Plus Co., Ltd., established in 2014.EndoClot Plus generates revenue through direct sales of its medical devices, particularly the EndoClot® product line, to healthcare institutions and professionals. Transactions typically occur on a B2B basis, where hospitals and clinics purchase these devices to utilize in endoscopic procedures. The pricing structure reflects the value of the innovative technology and its application in critical gastrointestinal interventions. Additionally, the company may engage in partnerships with healthcare providers to facilitate bulk purchasing agreements or distribute products through medical supply wholesalers. This transactional framework supports EndoClot Plus in establishing a steady revenue stream while catering to the growing demands of gastrointestinal healthcare.EndoClot Plus, Inc. is actively focusing on the development of new products aimed at enhancing its medical device offerings, although specific details and release dates have not been disclosed. The company plans to expand its market presence in China, leveraging its subsidiary established in 2014 to penetrate this growing healthcare market. The SERIES B funding raised in October 2018 will be utilized to support these initiatives, although the precise allocation of funds has not been specified.

## Funding rounds

- Series B, Oct 26, 2018 — Ming Bioventures

## Investors

- Ming Bioventures (https://capitalatlas.ai/funds/ming-bioventures) — Series B